Indeed, the value of diagnostic biomarkers is clearly seen in the utility of detecting thyroglobulin for monitoring thyroid cancer, and in administering Herceptin specifically for breast cancers overexpressing HER2/neu [4]. The gene discussed is ERBB2; the disease is thyroid gland carcinoma.